Will Novavax, Inc. (NVAX) Beat Its Last Earnings Report?

Will Novavax, Inc. (NVAX) Beat Its Last Earnings Report?

Novavax, Inc. (NVAX), a Biotechnology business, was a active mover in the prior session. Novavax, Inc. (NVAX) shares opened at $18.10 and closed the day at $19.08 with positive move of +5.41%. The increase change in Novavax, Inc. (NVAX) beat the change in the S&P 500 for the day which gained +2.68% in prior session.

Novavax, Inc. (NVAX) is focused on the Biotechnology sector. This market sector has seen some movement from day traders in recent days. Bullish day traders of Novavax, Inc. (NVAX) will be looking for positive upcoming earnings whereas bearish day traders of Novavax, Inc. (NVAX) will be looking for negative earnings. The last time Novavax, Inc. (NVAX) had an earnings surprise was on Qtr Ending 12/19 when they reported -$1.13 compared to an estimate of -$1.08 which was a difference of -$0.05 resulting in a change of -4.63%. Current earnings estimates are to be released for Current Qtr 03/2020 on Novavax, Inc. (NVAX) and out of 3 Wall Street estimates the average is saying -$0.65. The high estimate is saying -$0.57 whereas the low estimate is saying -$0.75 and the prior year Novavax, Inc. (NVAX) announced earnings at -$2.20 a growth rate est. (year over year) of +70.45%.

The market performance of Novavax, Inc. (NVAX) has varied recently. Year to date Novavax, Inc. (NVAX)’s shares are up 379.40%. Over the past 12 weeks Novavax, Inc. (NVAX) is up 149.09% and over the last 4 weeks Novavax, Inc. (NVAX) is up 64.77%. Novavax, Inc. (NVAX) current income statement shows revenue (ttm) of $18.66M. Gross Profit is $-95.18M. This puts the current EBITDA of Novavax, Inc. (NVAX) at $-123.92M.

Wall street day traders might also notice recent changes to stock analyst estimates for Novavax, Inc. (NVAX). The stock is trading with an RSI (relative strength index) of 69.63 indicating Novavax, Inc. (NVAX) is neither overbought nor oversold. Technically, NVAX’s short term support levels are around $12.14, $174.19 and $165.30 on the downside. NVAXs short term resistance levels are $23.72, $23.12 and $22.49 on the upside. The market cap of Novavax, Inc. (NVAX) is $983.169M and institutions hold 13.27% of the stock. The outstanding share count stands at 49.91M while the short float (shares short) stands at 7.09%.

Research shows that these estimate changes look to be directly correlated with short-term shares prices. The day traders can look to capitalize on the basis of ranking. Novavax, Inc. (NVAX) has short term rating of Bullish (0.28), Intermediate rating of Bullish (0.49) and long-term rating of Bullish (0.26) giving Novavax, Inc. (NVAX) an overall rating of Bullish (0.34).

The EPS growth this year on Novavax, Inc. (NVAX) is increased 44.90% and is expected to increase 8.40% next year. However, quarterly earnings (EPS) growth year over year on Novavax, Inc. (NVAX) has increased by 56.00% and quarterly revenue (Sales) growth year over year stands at 44.30%. Return on equity (ttm) is 74.60%.

Recent Developments:

2020-04-08 – Novavax Identifies Coronavirus Vaccine Candidate Accelerates Initiation Of First-In-Human Trial To Mid-May.
2020-03-24 – Novavax’ Nanoflu Achieves All Primary Endpoints In Phase 3 Clinical Trial.
2020-03-11 – Novavax And Serum Institute Of India To Develop And Commercialize Malaria Vaccine Candidate.
2020-03-02 – Novavax Says On March 2, Filed Prospectus Supplement With SEC Which Contemplates Sale Of Up To $150 Mln Shares.
2020-01-21 – Novavax Files For Offering Of Up To $100 Mln Of Common Stock.

About Company:

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products, and vaccine adjuvants.